Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald

June 9, 2026 7:18 AM

Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ: KPTI).The analyst commented, "we had the opportunity ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found